<code id='FB08D61422'></code><style id='FB08D61422'></style>
    • <acronym id='FB08D61422'></acronym>
      <center id='FB08D61422'><center id='FB08D61422'><tfoot id='FB08D61422'></tfoot></center><abbr id='FB08D61422'><dir id='FB08D61422'><tfoot id='FB08D61422'></tfoot><noframes id='FB08D61422'>

    • <optgroup id='FB08D61422'><strike id='FB08D61422'><sup id='FB08D61422'></sup></strike><code id='FB08D61422'></code></optgroup>
        1. <b id='FB08D61422'><label id='FB08D61422'><select id='FB08D61422'><dt id='FB08D61422'><span id='FB08D61422'></span></dt></select></label></b><u id='FB08D61422'></u>
          <i id='FB08D61422'><strike id='FB08D61422'><tt id='FB08D61422'><pre id='FB08D61422'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:focus    - browse:32372

          Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

          Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

          advertisement

          You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          hotspot